A McGill University-led research collaboration has achieved a breakthrough in understanding how cancer spreads. A clinical ...

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

A new class of molecules capable of killing the cancer cells that are refractory to standard treatments and responsible for recurrence has just been developed. This crucial advance in the fight ...

The treatment ... prostate cancer (mCRPC) involves a combination of therapies, including chemotherapy, hormone therapy, immunotherapy, and different medications that target bone metastases.

Or you may have treatment as part of a clinical trial. This page is about cancer that starts in your bone (primary bone cancer). If your cancer has spread into bone from another part of the body, it ...

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant ...

Renal cancer, or kidney cancer ... Doctors may order imaging tests to diagnose bone metastasis. A bone biopsy may also be necessary. Treatment will involve a multidisciplinary approach and ...

Then came another blow: Her insurance company wouldn’t cover the medication to keep the cancer under control. It cost $15,000 a month. “I was really worried,” remembers Stephanie, who had a new ...

Dr Olwyn Mahon on how she uses 3D models to understand tumour behaviour in urological cancers and why translating lab work to ...